SSStephen D. Shafran

Stephen D. Shafran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stephen D. Shafran has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance

    by Stephen D. Shafran, Christine A. Hughes

    Background: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is approved for treatment of HIV without known resistance to its components. Several studies have demonstrated efficacy of B/F/TAF in patients with nucleoside reverse transcriptase inhibitor (NRTI) resistance‐associated mutations (RAMs), mainly identified by proviral DNA testing, but data on the efficacy of B/F/TAF in patients with NRTI RAMs identified in viraemic plasma are limited.Methods: We used a retrospective analysis of patients receiving B/F/TAF identified by searching electronic health records with eligibility confirmed by review of individual patient records. Patients included were ≥ 18 years, had 2019 International Antiviral Socitey‐USA (IAS‐USA) major RAMs affecting NRTIs detected in viraemic plasma prior to starting B/F/TAF and one or more HIV viral load (VL) after starting B/F/TAF.Results: In all, 50 patients met the study criteria: mean age of 54 years, mean proximal CD4 count of 609 cells/μL, 64% male. A total of 46 were virologically suppressed (< 200 copies/mL) when B/F/TAF was initiated, two were treatment‐naïve, one stopped prior antiretroviral therapy (ART) and one had a VL of 961 HIV‐1 RNA copies/mL on ART. Twenty‐nine had one NRTI RAM (24 were M184V/I), nine had two NRTI RAMs, three had three NRTI RAMs, four had four NRTI RAMs, two had five NRTI RAMs, one had six NRTI RAMs, one had seven RAMs and one had eight NRTI RAMs. At the last VL on B/F/TAF, a mean of 18.6 months after starting B/F/TAF, 49 out of 50 had VL < 100 copies/mL and one had a VL of 208 copies/mL at 11 months but only filled 5 months of B/F/TAF.Conclusions: B/F/TAF was effective in maintaining HIV VL suppression in patients with previously documented NRTI RAMs without integrase resistance.


  • Open Access

    IDDF2019-ABS-0136 Sofosbuvir/velpatasvir for 12 weeks is safe and effective in patients undergoing dialysis

    by Sergio Borgia, Janet Dearden, Yoav Lurie, Stephen Shafran, Ashley Brown, Robert Hyland, Sophia Lu, Svetlana Markova, Hadas Dvory-Sobol, Anu Osinusi, et al.

    Background Approved HCV treatments for patients on dialysis are associated with complexities including drug-drug interactions, baseline resistance testing and use of ribavirin. Despite higher concentrations of the primary circulating sofosbuvir (SOF) metabolite, GS-331007, in severe renal impairment, real-world cases demonstrated substantial use of SOF-based regimens in this population without safety concerns identified. This study evaluated the safety, efficacy, and pharmacokinetics (PK) of SOF/velpatasvir (VEL) for 12 weeks in patients with HCV infection on dialysis. Methods Treatment-naive or -experienced patients, of any genotype, with or without compensated cirrhosis undergoing hemodialysis or peritoneal dialysis, were enrolled to receive open-label SOF/VEL (400/100 mg) once daily for 12 weeks. The primary efficacy endpoint was a comparison of the SVR12 to a prespecified historic control rate of 83%. The primary safety endpoint was the proportion of patients who discontinued therapy due to adverse events (AEs). Secondary endpoints included safety, viral resistance and PK. Results 59 patients were enrolled at 21 sites in Canada, United Kingdom, Spain, Israel, Australia and New Zealand. The median age was 62 years (range 49–86), 59% were male, 53% white, 32% treatment experienced, 29% had cirrhosis. Most patients had HCV genotype 1 (42%), or 3 (27%). Most (92%) were on hemodialysis with a mean dialysis duration of 7.3 years. Treatment was well tolerated; no one discontinued therapy due to AEs. One patient was discontinued therapy on day 74 for non-compliance with 48% study medication adherence by pill count. Overall, 56/59 (95%) of patients achieved SVR12. Two (3%) had virologic relapse (one with non-adherence). One patient did not achieve SVR12 due to death from suicide after SVR4. Exposures were consistent with the Phase 1 renal impairment study. The most frequent AEs were headache, fatigue, nausea, and vomiting. Serious AEs occurred in 19% of patients, none was assessed as related to study drug. Conclusions Treatment with SOF/VEL for 12 weeks in patients with and without cirrhosis undergoing dialysis resulted in a 95% SVR12 rate. The regimen was safe and well-tolerated with no treatment-related discontinuations or treatment-related SAEs.


  • Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II‐III)

    by S. D. Shafran, D. Shaw, M. Charafeddine, K. Agarwal, G. R. Foster, M. Abunimeh, T. Pilot‐Matias, R. K. Pothacamury, B. Fu, E. Cohen, et al.

    Summary: The efficacy and safety of an investigational combination of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) plus sofosbuvir (SOF) ± ribavirin (RBV) in patients with HCV genotype 2 or 3 infection with or without cirrhosis was evaluated. Patients with HCV genotype 3 infection without cirrhosis were randomized to receive OBV/PTV/r + SOF ± RBV for 12 weeks; OBV/PTV/r + SOF + RBV was administered to genotype 3‐infected patients with cirrhosis for 12 weeks and to genotype 2‐infected patients without cirrhosis for either 6 or 8 weeks. Efficacy was assessed by sustained virologic response [HCV RNA <25 IU/mL] 12 weeks post‐treatment (SVR12). Safety was assessed in all treated patients. In patients with genotype 3 infection with or without cirrhosis treated with 12 weeks of OBV/PTV/r + SOF ± RBV, the overall SVR12 rate was 98% (50/51), with no virologic failures. Patients with genotype 2 infection treated with OBV/PTV/r + SOF + RBV had SVR12 rates of 90% (9/10) and 44% (4/9) following 8‐ and 6‐week treatment durations, respectively; failure to achieve SVR12 for these patients was due to relapse without baseline or treatment‐emergent resistance‐associated substitutions. Thus, the investigational combination of OBV/PTV/r with SOF ± RBV was well tolerated and achieved high SVR rates with no virologic failures in patients with genotype 3 infection. Combining direct‐acting antivirals with complementary mechanisms of action and different viral targets may be an effective treatment strategy that may allow for shorter durations of therapy.


  • Open Access

    CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment

    by Mark Hull, Stephen Shafran, Alex Wong, Alice Tseng, Pierre Giguère, Lisa Barrett, Shariq Haider, Brian Conway, Marina Klein, Curtis Cooper

    Background. Hepatitis C virus (HCV) coinfection occurs in 20–30% of Canadians living with HIV and is responsible for a heavy burden of morbidity and mortality.Purpose. To update national standards for management of HCV-HIV coinfected adults in the Canadian context with evolving evidence for and accessibility of effective and tolerable DAA therapies. The document addresses patient workup and treatment preparation, antiviral recommendations overall and in specific populations, and drug-drug interactions.Methods. A standing working group with HIV-HCV expertise was convened by The Canadian Institute of Health Research HIV Trials Network to review recently published HCV antiviral data and update Canadian HIV-HCV Coinfection Guidelines.Results. The gap in sustained virologic response between HCV monoinfection and HIV-HCV coinfection has been eliminated with newer HCV antiviral regimens. All coinfected individuals should be assessed for interferon-free, Direct Acting Antiviral HCV therapy. Regimens vary in content, duration, and success based largely on genotype. Reimbursement restrictions forcing the use of pegylated interferon is not acceptable if optimal patient care is to be provided.Discussion. Recommendations may not supersede individual clinical judgement. Treatment advances published since December 2015 are not considered in this document.


  • 753 High SVR Rates With ABT-493 + ABT-530 Co-Administered for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 3 Infection

    by Andrew Muir, Simone Strasser, Stanley Wang, Stephen D. Shafran, Maurizio Bonacini, Paul Y. Kwo, David L. Wyles, Edward Gane, Sandra S. Lovell, Chih-Wei Lin, et al.


  • Open Access

    HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials

    by Stephen D. Shafran

    Phase 3 trials of direct acting antiviral drugs (DAAs) for hepatitis C virus (HCV) excluded patients coinfected with human immunodeficiency virus (HIV). After approval, small trials were done in HIV-HCV coinfected patients. The status quo results in delayed access to DAAs for HIV coinfected patients, a group with more rapid progression of liver disease. This article reviews all approved DAAs and compares sustained virological response (SVR) rates in the HIV coinfected with those in the HCV monoinfected treated with the same regimen for the same HCV genotype. SVR rates in HCV genotype 1 to 4 are virtually identical in the HIV co-infected as in the HCV monoinfected, regardless of whether the regimens contain interferon. Because HIV coinfection does not affect SVR rates or toxicity with DAA-containing therapy, excluding HIV coinfected patients from clinical trials of DAA-containing anti-HCV therapy is discriminatory and unnecessary. Rather, HIV coinfection is one of many comorbidities that occur in some patients with HCV infection.


  • Open Access

    The Hepatitis C Genotype 1 Paradox: Cost per Treatment Is Increasing, but Cost per Cure Is Decreasing

    by Stephen D Shafran

    Significant attention has been focused on the perceived increase in the cost of antiviral treatment for hepatitis C genotype 1 infection since the approval of the first direct-acting antiviral agents in 2011. Using Canadian list prices, the present analysis points out a paradox: while the cost per antiviral regimen is increasing, the cost per cure is decreasing, especially with interferon-free therapy. In a publicly funded health care system, the lowest cost per cure is a more valuable measure of value for public money than the cost per regimen.


  • Open Access

    Hepatitis C and the Sex Trade

    by Stephen D Shafran

    I t is well documented that female sex workers (FSWs) have high rates of substance abuse and sexually transmitted infections (1,2). Hepatitis C virus (HCV) is a blood borne virus transmitted principally by parenteral exposures, most commonly from illicit injection drug use (IDU) in the 'developed' world and health care-related exposures due to inadequate infection prevention measures in the 'developing' world. Mother-to-child transmission occurs in approximately 5% of pregnancies among HCV viremic women (3). Sexual transmission of HCV has been studied extensively, and heterosexual transmission is rare, estimated to be only one per 190,000 heterosexual contacts (4). In contrast, sexual transmission among HIV-infected men who have sex with men (MSM) is far more efficient and is an ongoing global challenge (5). Unprotected receptive anal intercourse and use of amphetamines are demonstrated risk factors for sexual transmission of HCV among HIV-infected MSM (5). Multiple studies have examined the prevalence of HCV infection in FSWs (6-11). In some locations, FSWs have high rates of present or past IDU, placing them at high risk for HCV infection (9,10). Studies that have controlled for IDU have not found higher rates of HCV infection among FSWs with no history of IDU (11). The study by Socías et al (12) in the current issue of the Journal (pages 411-416), from An Evaluation of Sex Workers' Health Access (AESHA) cohort of FSW in Vancouver, British Columbia, purports to demonstrate gaps in the continuum of care for HCV among FSW. In fact, studies of the continuum of HCV care in the general population have shown very low rates of antiviral treatment. In Philadelphia (Pennsylvania, USA), it is estimated that only 15% of HCV-infected individuals receive antiviral therapy (13). The study by Socías et al (12) is significantly limited by methodology. They relied entirely on patient self-reporting regarding HCV diagnosis, accessing HCV care, being offered anti-HCV therapy and receiving antiviral therapy. No effort was made to verify the data, even in a subset of patients. The authors repeatedly suggest that the FSWs are at increased risk for HCV infection by the sexual route. To quote the authors "women sex workers in Vancouver had evidence of current/past HCV infection, likely due to the dual parenteral and sexual routes". This statement is patently false and detracts from the message that FSWs have high rates of HCV infection, because 51% of this cohort of women provided a history of IDU. The authors also appear to misunderstand risk-based HCV testing. They defined it as "targeting individuals perceived to be at high risk for HCV infection, including people who use injection drugs, or with clinical or laboratory evidence of liver disease". These are not individuals 'perceived' to be at high risk for HCV, they are proven to be at high risk for HCV infection. In fact, >80% of Canadians with HCV infection have a history of IDU, and elevated serum alanine aminotransferase level is the most common reason physicians order HCV serology in patients of unknown HCV status. The authors did not evaluate or discuss how to optimally engage FSWs in successful HCV care, which I define as achieving a sustained virological response (SVR) without re-infection. However, in another study of the AESHA cohort by several of the same authors, it was noted